Using dual-energy x-ray absorptiometry (DEXA) measurements, which estimate lean soft tissue, including skeletal muscle, ...
Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, ...
As a drug targeting lipoprotein (a), or Lp (a), failed to prevent cardiovascular events in a closely-watched clinical trial, ...
Generally, experts say, the answer is no. "Most people are protected without getting a booster shot" because they've either ...
Bernstam, MD, of the University of Texas MD Anderson Cancer Center in Houston, discusses the findings and how torvu-sam could ...
On November 9, FDA announced it is requiring new warnings across all products in the GLP-1 drug class, which includes ...
What does it mean for the U.S. to lose its measles elimination status after more than 25 years -- and what will it take to ...
Sen. Bernie Sanders (I-Vt.) is preparing to use his return atop a powerful Senate committee to push for sweeping changes to ...
Medline beds, rails, mattresses, and accessories recalled over potential fire and entrapment hazards have been linked with ...
The FDA approved adrabetadex (Lembaz) injection on Tuesday for patients with infantile-onset Niemann-Pick disease type C (NPC ...
When the federal funding ran dry, Diannee Carden Glenn's options were few. Carden Glenn is the director of ekiM for Change, a volunteer-run public health organization that works to prevent overdoses ...
In this first of five exclusive episodes, the panel discusses emerging treatment, including triple agonists, amylin analogs, and other novel approaches that could reshape obesity care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results